Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for end-stage renal disease/mortality in type 2 diabetes

HM Campbell, N Khan, DW Raisch, ME Borrego… - Diabetes Research and …, 2013 - Elsevier
Aims To compare angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin
receptor blockers (ARBs) for end-stage renal disease (ESRD) development and all-cause …
被引用次数：9 相关文章

Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for end-stage renal disease/mortality in type 2 diabetes.

HM Campbell, N Khan, DW Raisch… - … and Clinical Practice, 2013 - europepmc.org
Aims To compare angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin
receptor blockers (ARBs) for end-stage renal disease (ESRD) development and all-cause …

Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for end-stage renal disease/mortality in type 2 diabetes

HM Campbell, N Khan… - Diabetes …, 2013 - diabetesresearchclinicalpractice …
Aims To compare angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin
receptor blockers (ARBs) for end-stage renal disease (ESRD) development and all-cause …

Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for end-stage renal disease/mortality in type 2 diabetes

HM Campbell, N Khan, DW Raisch, ME Borrego… - Diabetes Research and …, 2013 - infona.pl
To compare angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor
blockers (ARBs) for end-stage renal disease (ESRD) development and all-cause mortality in …

Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for end-stage renal disease/mortality in type 2 diabetes

HM Campbell, N Khan, DW Raisch… - Diabetes research …, 2013 - pubmed.ncbi.nlm.nih.gov
Aims To compare angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin
receptor blockers (ARBs) for end-stage renal disease (ESRD) development and all-cause …